The Faces of iPSpine

INSERM
What is your team's main scientific expertise/contribution to the iPSpine project?

My main expertise is focused on the use of stem cells for tissue engineering and cell therapy approaches in osteo-articular diseases. In addition to conduct research projects, I am also the scientific leader of the EcellFrance platform on pre-clinical and safety evaluation models. Within this context, we have set up protocols and analysis techniques to evaluate the safety of Advanced Therapeutic Medicinal Products (ATMP) in murine models.

Within iPSpine, the safety of implanted iPS-NLCs has to be demonstrated in pre-clinical models. We will evaluate the biodistribution of iPS-NLCs with or without the selected biomaterials after implantation or systemic injection in mice. We will also perform toxicity assays and pathophysiological analysis to determine whether the cells and/or the biomaterials might have adverse side effects.

Danièle Noël

Research director

How does it feel to be working in such a large consortium?

Within iPSpine, the safety of implanted iPS-NLCs has to be demonstrated in pre-clinical models. We will evaluate the biodistribution of iPS-NLCs with or without the selected biomaterials after implantation or systemic injection in mice. We will also perform toxicity assays and pathophysiological analysis to determine whether the cells and/or the biomaterials might have adverse side effects.

What do you think is unique about being part of the iPSpine project?

The iPSpine community gathers the scientific experts working on Spine diseases from across Europe and this is a fantastic opportunity to be part of this exciting project.